December 16, 2025 Is the era within which a TURP was performed associated with differences in reoperation rates, specific surgical side effects, or the requirement for BPH medicat ...

Antioxidants for Male Infertility: Therapeutic Scheme and Indications. A Retrospective Single-Center Real-Life Study - Beyond the Abstract ...

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...

Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...

Does Adjuvant Immune Checkpoint Inhibition Therapy Have a Future in Operable Bladder Cancer? December 18, 2025 Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical ...

Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment. December 12, 2025 Predicting Toxicities and Survival Outcomes in De Novo Metastatic ...

Read the Full Video Transcript Neeraj Agarwal: Welcome to UroToday. Today we have Dr. Arun Azad, Associate Professor and a medical oncologist specializing in genitourinary cancers at the Peter ...

Alicia Morgans discusses a study with Stacy Loeb, exploring the impact of a plant-based diet on prostate cancer survivors, based on Loeb's paper published in Cancer. Dr. Loeb, motivated by clinical ...

Read the Full Video Transcript Rashid Sayyid: Hello, everyone, and thank you for joining us today in this UroToday recording. I'm Rashid Sayyid, robotic urology and oncology fellow at USC, and I'm ...

Read the Full Video Transcript Zach Klaassen: Hi, my name is Dr. Zach Klaassen, and I'm a urologic oncologist at the Georgia Cancer Center in Augusta, Georgia. And we're here in San Francisco at ...

Sam Chang speaks with Sarah Psutka about an expanded access program for cretostimogene (CG0070) in BCG-unresponsive non-muscle invasive bladder cancer. Dr. Psutka explains that this oncolytic ...

Michael Schweizer discusses findings on Mevrometostat, an EZH2 inhibitor, combined with enzalutamide in treating metastatic castration-resistant prostate cancer (mCRPC). Dr. Schweizer highlights that ...